OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PCa) will occur. With an estimated 27,540 deaths in 2015, PCa is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in the treatment of PCa to assist medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, urologists and other healthcare practitioners in the formulation of up-to-date and appropriate treatment strategies.

LEARNING OBJECTIVES

• Consider the decision-making of clinical investigators with expertise in the management of metastatic castration-resistant PCa, and use this information in the future selection of treatment regimens — with or without bone-targeted therapy — for patients with this disease.
• Assess the effects of patient- and disease-specific factors such as patient age and level of tumor burden on treatment preferences for patients with metastatic castration-resistant PCa.
• Evaluate sequencing approaches to abiraterone and enzalutamide and the probability of response to one after disease progression on the other.

ACCREDITATION STATEMENT

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a text component. The participant should review the treatment preference matrix.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Andrew J Armstrong, MD, ScM
Associate Professor of Medicine and Surgery
Duke Cancer Institute
Duke University
Durham, North Carolina

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Consulting Agreements: Active Biotech AB, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Ipsen, Sanofi; Contracted Research: Active Biotech AB, Astellas Scientific and Medical Affairs Inc, Bristol-Myers Squibb Company, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Ipsen, Janssen Biotech Inc, KangLaiTe USA, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Speakers Bureau: Amgen Inc, Dendreon Corporation, Pfizer Inc, Sanofi.

Johann S de Bono, MBChB, MSc, PhD
Professor of Experimental Cancer Medicine
and Honorary Consultant in Medical Oncology
Head of Clinical Studies Division,
of Drug Development Unit and of the Prostate Cancer Targeted Therapy Group
The Institute of Cancer Research and
Royal Marsden NHS Foundation Trust
Sycamore House
Sutton, Surrey, United Kingdom

Advisory Committee and Consulting Agreements: Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi; Contracted Research: Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Sanofi.

Prof Ronald de Wit, MD, PhD
Medical Oncologist
Erasmus MC Cancer Institute
Rotterdam, Netherlands

Advisory Committee: Sanofi, Takeda Oncology; Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Janssen Biotech Inc, Roche Laboratories Inc, Sanofi, Takeda Oncology; Contracted Research: Sanofi.

Leonard G Gomella, MD
The Bernard W Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Sidney Kimmel Cancer Center
Clinical Director, Jefferson Sidney Kimmel Cancer Center Network
Editor-in-Chief, Canadian Journal of Urology
Philadelphia, Pennsylvania

Advisory Committee: Dendreon Corporation, GlaxoSmithKline; Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc; Contracted Research: Astellas Scientific and Medical Affairs Inc, Dendreon Corporation, Janssen Biotech Inc.

Celestia S Higano, MD
Professor of Medicine and Urology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Advisory Committee: Abbott Laboratories, Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Takeda Oncology; Consulting Agreements: Abbott Laboratories, Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Pfizer Inc, Takeda Oncology; Contracted Research: Aragon Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Sanofi, Takeda Oncology, Teva Oncology; Co-ownership: CTI BioPharma. None of the products currently approved or in development at CTI BioPharma pertain to any form of treatment for prostate cancer. As such, Dr Higano’s involvement with CTI BioPharma does not pose any conflict of interest in her participation in this CME activity.

Philip Kantoff, MD
Chair, Executive Committee for Clinical Research
Chief Clinical Research Officer
Chief, Division of Solid Tumor Oncology
Vice Chair, Department of Medical Oncology
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Astellas Scientific and Medical Affairs Inc, Auven Therapeutics, Bellicum Pharmaceuticals Inc, BIND Therapeutics Inc, Blend Therapeutics, Endocyte/TRM Oncology, Medivation Inc, Metamark Genetics Inc, OncoCellMDx Inc, Progenics Pharmaceuticals Inc, Sanofi, SOTIO LLC, Tokai Pharmaceuticals Inc; Consulting Agreements: Amgen Inc, Aragon Pharmaceuticals Inc, Archimedes Pharma US Inc, Bayer HealthCare Pharmaceuticals, BN ImmunoTherapeutics Inc, Celgene Corporation, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, GTx Inc, Janssen Biotech Inc, MorphoSys, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Takeda Oncology, Teva Oncology/OncoGenex Pharmaceuticals Inc.

Eric A Klein, MD
Chairman, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, Ohio

Clinical Trial Support: Medivation Inc; Consulting Agreements: Genomic Health Inc, Medivation Inc; Contracted Research: Genomic Health Inc.

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi, Takeda Oncology; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Progenics Pharmaceuticals Inc, Sanofi, Takeda Oncology.

Neal D Shore, MD
Medical Director, Carolina Urology Research Center
Myrtle Beach, South Carolina

Consulting Agreements: Abbott Laboratories, Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi, Takeda Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Sanofi and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2015
Expiration date: March 2016